Ceprate SC PMA to be reviewed:
This article was originally published in Clinica
The US FDA's biological response modifiers advisory committee is due to discuss CellPro's PMA for the Ceprate SC device for selection of CD34+ progenitor/stem cells at its meeting on February 28th. Meanwhile, 134 patients are being enrolled for a Phase III US trial to use the system to deplete tumour cells from peripheral blood stem cell transplants in multiple myeloma treatment.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.